Dr Reddy is currently trading at Rs. 1712.95, up by 37.45 points or 2.24% from its previous closing of Rs. 1675.50 on the BSE.
The scrip opened at Rs. 1690.00 and has touched a high and low of Rs. 1717.35 and Rs. 1690.00 respectively. So far 24,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1,717.35 and Rs. 1636.05 respectively. The current market cap of the company is Rs. 29,063 crore.
The promoters holding in the company stood at 25.57% while Institutions and Non-Institutions held 40.32% and 17.32% respectively.
Dr Reddy’s Laboratories, country’s pharma major has decided to introduce its biosimilars in developed markets. biosimilars are used to treat patients suffering from cancer at a price that is significantly more affordable than the corresponding innovator drugs. During 2011-12, the company’s global biosimilars business earned $26 million revenue reporting 25% year-on-year growth.
Recently, the company entered into a partnership with Merck Serono, a division of Germany-based Merck KGaA, to co-develop biosimilar compounds. The collaboration was to concentrate on monoclonal antibodies (MAbs) in the oncology segment besides, manufacturing and commercialization of the compounds.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: